Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?
Objectives The European Association for the Study of the Liver (EASL) treatment recommendations for hepatitis C no longer discriminate between HIV/hepatitis C virus (HCV)‐coinfected and HCV‐monoinfected patients. However, recent data from Spain are questioning these recommendations on the basis of t...
Gespeichert in:
| Veröffentlicht in: | HIV medicine 2018-04, Vol.19 (4), p.299-307 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 307 |
|---|---|
| container_issue | 4 |
| container_start_page | 299 |
| container_title | HIV medicine |
| container_volume | 19 |
| creator | Bischoff, J Mauss, S Cordes, C Lutz, T Scholten, S Moll, A Jäger, H Cornberg, M Manns, MP Baumgarten, A Rockstroh, JK |
| description | Objectives
The European Association for the Study of the Liver (EASL) treatment recommendations for hepatitis C no longer discriminate between HIV/hepatitis C virus (HCV)‐coinfected and HCV‐monoinfected patients. However, recent data from Spain are questioning these recommendations on the basis of the findings of higher relapse rates and lower cure rates in HIV/HCV‐infected subjects. The aim of our study was to compare HCV cure rates in monoinfected and coinfected patients from Germany.
Methods
Data acquired from the Deutsches Hepatitis C‐Registry were analysed. A total of 5657 HCV‐monoinfected subjects and 488 HIV/HCV‐coinfected patients were included in the study. Rates of sustained virological response 12 weeks after the scheduled end of therapy (SVR12) were collected in both subgroups and in cirrhotic and noncirrhotic patients.
Results
HIV/HCV‐coinfected patients were more frequently male (84.6% vs. 56.4%, respectively; P |
| doi_str_mv | 10.1111/hiv.12579 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1991183322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2017689318</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3039-bad967baaa9debd50fd857a87edf3bd7f0a4ab659f8f12654516c5fc0027aaf33</originalsourceid><addsrcrecordid>eNp1ks9u1DAQhwMC0bJw4AWQJS67h7RxnL-9oNUC3UoVSAh6jSbxeNcliYPttNobj8Aj8Cw8Ck_C7KbtAQlfbGk-f7-RPUHwikcnnNbpVt-c8DjNy8fBMU-yIuRxKZ4czkkYZ1l8FDx37jqKeC7K6FlwROWsSNLs-FHwGTw6ZhRzo_Oge5TsRlvTmo1uoGUW3WB6h4zHv3_dIn5zDJRHy_wWmWu2KMeWrmAv9w6pLTb-z4-f0Hjdbxj0XpONPPN3y-WCCjU4wrc4gNdeO7bap42Ozderq8VeamHYMWVNd0j4SJjp6f452g56RhS1tNHO290Zk4ZaX19cscboXlEysUx3A-ipv4fmvWGUT1hX6_6gvI96-yJ4qqB1-PJunwVfP7z_slqHl5_OL1bLy7ARkSjDGmSZ5TUAlBJrmUZKFmkORY5SiVrmKoIE6iwtVaF4nKVJyrMmVU0UxTmAEmIWzCfvYM33EZ2vOu0abFvo0Yyu4mXJeSFEHBP65h_02oyWXsFVMX1hVpSCyFmwmKjGGucsqmqwugO7q3hU7ceiorGoDmNB7Os741h3KB_I-zkg4HQCbnWLu_-bKnrtSfkX0CjH0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2017689318</pqid></control><display><type>article</type><title>Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?</title><source>Wiley Free Content</source><source>Wiley Online Library - AutoHoldings Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Bischoff, J ; Mauss, S ; Cordes, C ; Lutz, T ; Scholten, S ; Moll, A ; Jäger, H ; Cornberg, M ; Manns, MP ; Baumgarten, A ; Rockstroh, JK</creator><creatorcontrib>Bischoff, J ; Mauss, S ; Cordes, C ; Lutz, T ; Scholten, S ; Moll, A ; Jäger, H ; Cornberg, M ; Manns, MP ; Baumgarten, A ; Rockstroh, JK</creatorcontrib><description>Objectives
The European Association for the Study of the Liver (EASL) treatment recommendations for hepatitis C no longer discriminate between HIV/hepatitis C virus (HCV)‐coinfected and HCV‐monoinfected patients. However, recent data from Spain are questioning these recommendations on the basis of the findings of higher relapse rates and lower cure rates in HIV/HCV‐infected subjects. The aim of our study was to compare HCV cure rates in monoinfected and coinfected patients from Germany.
Methods
Data acquired from the Deutsches Hepatitis C‐Registry were analysed. A total of 5657 HCV‐monoinfected subjects and 488 HIV/HCV‐coinfected patients were included in the study. Rates of sustained virological response 12 weeks after the scheduled end of therapy (SVR12) were collected in both subgroups and in cirrhotic and noncirrhotic patients.
Results
HIV/HCV‐coinfected patients were more frequently male (84.6% vs. 56.4%, respectively; P < 0.001) and younger than HCV‐monoinfected subjects (46.5 ± 9 vs. 53.8 ± 12.5 years, respectively; P < 0.001). The CD4 blood cell count was > 350 cells/μL in 63.1% of HIV‐positive subjects and 88.7% were on antiretroviral therapy. SVR12 rates were 90.3% (5111 of 5657) in our HCV‐monoinfected cohort and 91.2% (445 of 488) in our coinfected patients. Liver cirrhosis was confirmed in 1667 of 5657 (29.5%) monoinfected patients and 84 of 488 (17.2%; P < 0.001) coinfected patients. SVR12 rates did not differ between HCV‐monoinfected and HIV/HCV‐coinfected patients with liver cirrhosis (87.8% vs. 89.3%, respectively; P = 0.864). A treatment duration of 8 weeks did not reduce the percentage of patients with SVR12 in either subgroup (93.7% in both groups).
Conclusions
We found high SVR12 rates in monoinfected as well as coinfected individuals. No differences were detected between the two subgroups regardless of whether there was accompanying liver cirrhosis or a shortened treatment duration.</description><identifier>ISSN: 1464-2662</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/hiv.12579</identifier><identifier>PMID: 29368456</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>12‐week sustained virological response ; Antiretroviral agents ; Antiretroviral therapy ; Blood cells ; CD4 antigen ; chronic hepatitis C ; Cirrhosis ; Data acquisition ; direct‐acting antivirals ; Hepatitis ; Hepatitis C ; hepatitis C virus/HIV coinfection ; HIV ; Human immunodeficiency virus ; Liver ; Liver cirrhosis ; Patients ; real world effectiveness ; Subgroups ; Therapy ; Viruses</subject><ispartof>HIV medicine, 2018-04, Vol.19 (4), p.299-307</ispartof><rights>2018 British HIV Association</rights><rights>2018 British HIV Association.</rights><rights>HIV Medicine © 2018 British HIV Association</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3039-bad967baaa9debd50fd857a87edf3bd7f0a4ab659f8f12654516c5fc0027aaf33</citedby><cites>FETCH-LOGICAL-c3039-bad967baaa9debd50fd857a87edf3bd7f0a4ab659f8f12654516c5fc0027aaf33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhiv.12579$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhiv.12579$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29368456$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bischoff, J</creatorcontrib><creatorcontrib>Mauss, S</creatorcontrib><creatorcontrib>Cordes, C</creatorcontrib><creatorcontrib>Lutz, T</creatorcontrib><creatorcontrib>Scholten, S</creatorcontrib><creatorcontrib>Moll, A</creatorcontrib><creatorcontrib>Jäger, H</creatorcontrib><creatorcontrib>Cornberg, M</creatorcontrib><creatorcontrib>Manns, MP</creatorcontrib><creatorcontrib>Baumgarten, A</creatorcontrib><creatorcontrib>Rockstroh, JK</creatorcontrib><title>Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description>Objectives
The European Association for the Study of the Liver (EASL) treatment recommendations for hepatitis C no longer discriminate between HIV/hepatitis C virus (HCV)‐coinfected and HCV‐monoinfected patients. However, recent data from Spain are questioning these recommendations on the basis of the findings of higher relapse rates and lower cure rates in HIV/HCV‐infected subjects. The aim of our study was to compare HCV cure rates in monoinfected and coinfected patients from Germany.
Methods
Data acquired from the Deutsches Hepatitis C‐Registry were analysed. A total of 5657 HCV‐monoinfected subjects and 488 HIV/HCV‐coinfected patients were included in the study. Rates of sustained virological response 12 weeks after the scheduled end of therapy (SVR12) were collected in both subgroups and in cirrhotic and noncirrhotic patients.
Results
HIV/HCV‐coinfected patients were more frequently male (84.6% vs. 56.4%, respectively; P < 0.001) and younger than HCV‐monoinfected subjects (46.5 ± 9 vs. 53.8 ± 12.5 years, respectively; P < 0.001). The CD4 blood cell count was > 350 cells/μL in 63.1% of HIV‐positive subjects and 88.7% were on antiretroviral therapy. SVR12 rates were 90.3% (5111 of 5657) in our HCV‐monoinfected cohort and 91.2% (445 of 488) in our coinfected patients. Liver cirrhosis was confirmed in 1667 of 5657 (29.5%) monoinfected patients and 84 of 488 (17.2%; P < 0.001) coinfected patients. SVR12 rates did not differ between HCV‐monoinfected and HIV/HCV‐coinfected patients with liver cirrhosis (87.8% vs. 89.3%, respectively; P = 0.864). A treatment duration of 8 weeks did not reduce the percentage of patients with SVR12 in either subgroup (93.7% in both groups).
Conclusions
We found high SVR12 rates in monoinfected as well as coinfected individuals. No differences were detected between the two subgroups regardless of whether there was accompanying liver cirrhosis or a shortened treatment duration.</description><subject>12‐week sustained virological response</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral therapy</subject><subject>Blood cells</subject><subject>CD4 antigen</subject><subject>chronic hepatitis C</subject><subject>Cirrhosis</subject><subject>Data acquisition</subject><subject>direct‐acting antivirals</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>hepatitis C virus/HIV coinfection</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Patients</subject><subject>real world effectiveness</subject><subject>Subgroups</subject><subject>Therapy</subject><subject>Viruses</subject><issn>1464-2662</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp1ks9u1DAQhwMC0bJw4AWQJS67h7RxnL-9oNUC3UoVSAh6jSbxeNcliYPttNobj8Aj8Cw8Ck_C7KbtAQlfbGk-f7-RPUHwikcnnNbpVt-c8DjNy8fBMU-yIuRxKZ4czkkYZ1l8FDx37jqKeC7K6FlwROWsSNLs-FHwGTw6ZhRzo_Oge5TsRlvTmo1uoGUW3WB6h4zHv3_dIn5zDJRHy_wWmWu2KMeWrmAv9w6pLTb-z4-f0Hjdbxj0XpONPPN3y-WCCjU4wrc4gNdeO7bap42Ozderq8VeamHYMWVNd0j4SJjp6f452g56RhS1tNHO290Zk4ZaX19cscboXlEysUx3A-ipv4fmvWGUT1hX6_6gvI96-yJ4qqB1-PJunwVfP7z_slqHl5_OL1bLy7ARkSjDGmSZ5TUAlBJrmUZKFmkORY5SiVrmKoIE6iwtVaF4nKVJyrMmVU0UxTmAEmIWzCfvYM33EZ2vOu0abFvo0Yyu4mXJeSFEHBP65h_02oyWXsFVMX1hVpSCyFmwmKjGGucsqmqwugO7q3hU7ceiorGoDmNB7Os741h3KB_I-zkg4HQCbnWLu_-bKnrtSfkX0CjH0Q</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Bischoff, J</creator><creator>Mauss, S</creator><creator>Cordes, C</creator><creator>Lutz, T</creator><creator>Scholten, S</creator><creator>Moll, A</creator><creator>Jäger, H</creator><creator>Cornberg, M</creator><creator>Manns, MP</creator><creator>Baumgarten, A</creator><creator>Rockstroh, JK</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201804</creationdate><title>Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?</title><author>Bischoff, J ; Mauss, S ; Cordes, C ; Lutz, T ; Scholten, S ; Moll, A ; Jäger, H ; Cornberg, M ; Manns, MP ; Baumgarten, A ; Rockstroh, JK</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3039-bad967baaa9debd50fd857a87edf3bd7f0a4ab659f8f12654516c5fc0027aaf33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>12‐week sustained virological response</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral therapy</topic><topic>Blood cells</topic><topic>CD4 antigen</topic><topic>chronic hepatitis C</topic><topic>Cirrhosis</topic><topic>Data acquisition</topic><topic>direct‐acting antivirals</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>hepatitis C virus/HIV coinfection</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Patients</topic><topic>real world effectiveness</topic><topic>Subgroups</topic><topic>Therapy</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bischoff, J</creatorcontrib><creatorcontrib>Mauss, S</creatorcontrib><creatorcontrib>Cordes, C</creatorcontrib><creatorcontrib>Lutz, T</creatorcontrib><creatorcontrib>Scholten, S</creatorcontrib><creatorcontrib>Moll, A</creatorcontrib><creatorcontrib>Jäger, H</creatorcontrib><creatorcontrib>Cornberg, M</creatorcontrib><creatorcontrib>Manns, MP</creatorcontrib><creatorcontrib>Baumgarten, A</creatorcontrib><creatorcontrib>Rockstroh, JK</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bischoff, J</au><au>Mauss, S</au><au>Cordes, C</au><au>Lutz, T</au><au>Scholten, S</au><au>Moll, A</au><au>Jäger, H</au><au>Cornberg, M</au><au>Manns, MP</au><au>Baumgarten, A</au><au>Rockstroh, JK</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2018-04</date><risdate>2018</risdate><volume>19</volume><issue>4</issue><spage>299</spage><epage>307</epage><pages>299-307</pages><issn>1464-2662</issn><eissn>1468-1293</eissn><abstract>Objectives
The European Association for the Study of the Liver (EASL) treatment recommendations for hepatitis C no longer discriminate between HIV/hepatitis C virus (HCV)‐coinfected and HCV‐monoinfected patients. However, recent data from Spain are questioning these recommendations on the basis of the findings of higher relapse rates and lower cure rates in HIV/HCV‐infected subjects. The aim of our study was to compare HCV cure rates in monoinfected and coinfected patients from Germany.
Methods
Data acquired from the Deutsches Hepatitis C‐Registry were analysed. A total of 5657 HCV‐monoinfected subjects and 488 HIV/HCV‐coinfected patients were included in the study. Rates of sustained virological response 12 weeks after the scheduled end of therapy (SVR12) were collected in both subgroups and in cirrhotic and noncirrhotic patients.
Results
HIV/HCV‐coinfected patients were more frequently male (84.6% vs. 56.4%, respectively; P < 0.001) and younger than HCV‐monoinfected subjects (46.5 ± 9 vs. 53.8 ± 12.5 years, respectively; P < 0.001). The CD4 blood cell count was > 350 cells/μL in 63.1% of HIV‐positive subjects and 88.7% were on antiretroviral therapy. SVR12 rates were 90.3% (5111 of 5657) in our HCV‐monoinfected cohort and 91.2% (445 of 488) in our coinfected patients. Liver cirrhosis was confirmed in 1667 of 5657 (29.5%) monoinfected patients and 84 of 488 (17.2%; P < 0.001) coinfected patients. SVR12 rates did not differ between HCV‐monoinfected and HIV/HCV‐coinfected patients with liver cirrhosis (87.8% vs. 89.3%, respectively; P = 0.864). A treatment duration of 8 weeks did not reduce the percentage of patients with SVR12 in either subgroup (93.7% in both groups).
Conclusions
We found high SVR12 rates in monoinfected as well as coinfected individuals. No differences were detected between the two subgroups regardless of whether there was accompanying liver cirrhosis or a shortened treatment duration.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29368456</pmid><doi>10.1111/hiv.12579</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-2662 |
| ispartof | HIV medicine, 2018-04, Vol.19 (4), p.299-307 |
| issn | 1464-2662 1468-1293 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1991183322 |
| source | Wiley Free Content; Wiley Online Library - AutoHoldings Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 12‐week sustained virological response Antiretroviral agents Antiretroviral therapy Blood cells CD4 antigen chronic hepatitis C Cirrhosis Data acquisition direct‐acting antivirals Hepatitis Hepatitis C hepatitis C virus/HIV coinfection HIV Human immunodeficiency virus Liver Liver cirrhosis Patients real world effectiveness Subgroups Therapy Viruses |
| title | Rates of sustained virological response 12 weeks after the scheduled end of direct‐acting antiviral (DAA)‐based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T02%3A54%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rates%20of%20sustained%20virological%20response%2012%C2%A0weeks%20after%20the%20scheduled%20end%20of%20direct%E2%80%90acting%20antiviral%20(DAA)%E2%80%90based%20hepatitis%20C%20virus%20(HCV)%20therapy%20from%20the%20National%20German%20HCV%20registry:%20does%20HIV%20coinfection%20impair%20the%20response%20to%20DAA%20combination%20therapy?&rft.jtitle=HIV%20medicine&rft.au=Bischoff,%20J&rft.date=2018-04&rft.volume=19&rft.issue=4&rft.spage=299&rft.epage=307&rft.pages=299-307&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/hiv.12579&rft_dat=%3Cproquest_cross%3E2017689318%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2017689318&rft_id=info:pmid/29368456&rfr_iscdi=true |